First patient dosed in Part 2 of Verrica Pharmaceuticals' Phase II study evaluating LTX-315
Our licensing partner Verrica Pharmaceuticals today announced that the first patient has been dosed in Part 2 of their Phase II study evaluating our lead compound, LTX-315 - by Verrica designated as VP-315 - for treatment of basal cell carcinoma.
The progress into Part 2 is based on the positive results from the recently completed Part 1 of the study, where LTX-315 showed clinical evidence of activity in patients who received a higher dose range.
The CEO of Verrica, Ted White, made this comment: “As a novel oncolytic peptide administered directly at the tumor site, VP-315 has the potential to offer a non-surgical alternative for the approximately 3.6 million cases of basal cell carcinoma diagnosed in the U.S. each year.”
For the entire press release from Verrica, click here.